How much funding has Veracyte raised?

Veracyte has raised $56.3M in total funding, most recently a Series C round.

Who are Veracyte's investors?

Veracyte's investors include Domain Associates, TPG Biotech, Jerel Davis, GE Ventures.

What industry is Veracyte in?

Veracyte operates in Biotech, Diagnostics, Genomics, Healthcare, Oncology.

How many employees does Veracyte have?

Veracyte has 501-1000 employees.

Veracyte

Q: Where is Veracyte headquartered?

Veracyte is headquartered in South San Francisco, California, United States.

IPO

Empowering clinicians to diagnose and treat cancer with confidence

Public · South San Francisco, United States · Founded 2008 · $56.3M raised

Headquarters: South San Francisco, California
Employees: 501–1000
Founded: 2008
Business Model: B2B
Website: veracyte.com

Total Funding: $56.3M
Last Round: $28.0M Series CJun 2013
Rounds: 3
Type: Public

About

Veracyte is a global genomic diagnostics company founded in 2008 and headquartered in South San Francisco, California. The company develops and commercializes genomic tests that give clinicians high-confidence insights at critical diagnostic decision points in oncology. Its product portfolio includes the Afirma Genomic Sequencing Classifier for thyroid cancer, Decipher Prostate and Bladder Genomic Classifiers for urologic cancers, the Prosigna Breast Cancer Assay, and the Percepta Nasal Swab Test for lung cancer. Veracyte's tests enable physicians to avoid unnecessary surgeries and guide treatment decisions with greater precision. The company has grown through acquisitions and partnerships to serve patients and clinicians across multiple cancer types globally.

Summary

Veracyte is a Biotech company based in South San Francisco, United States, founded in 2008. It has raised $56.3M in total across 3 rounds, most recently a $28.0M Series C round in Jun 2013. Investors include Domain Associates, TPG Biotech and Jerel Davis.